A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 262 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 New targeted treatment for early breast cancer could reduce risk of... July 21, 2022 Long-Term Survival in a Significant Proportion of Patients with a 1p/19q... June 28, 2022 Managing Cancer Pain: Are Better Approaches on the Horizon? January 23, 2019 Load more HOT NEWS Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows When Natural Disasters Strike, This Program Helps Provide Relief To People... Man Walks Entire Continent To Spread Awareness About Mental Health &... A urine test for bladder cancer: What’s the latest?
